706 related articles for article (PubMed ID: 30938796)
1. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
Rabinovici GD; Gatsonis C; Apgar C; Chaudhary K; Gareen I; Hanna L; Hendrix J; Hillner BE; Olson C; Lesman-Segev OH; Romanoff J; Siegel BA; Whitmer RA; Carrillo MC
JAMA; 2019 Apr; 321(13):1286-1294. PubMed ID: 30938796
[TBL] [Abstract][Full Text] [Related]
2. Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
Rabinovici GD; Carrillo MC; Apgar C; Gareen IF; Gutman R; Hanna L; Hillner BE; March A; Romanoff J; Siegel BA; Smith K; Song Y; Weber C; Whitmer RA; Gatsonis C
JAMA Neurol; 2023 Nov; 80(11):1166-1173. PubMed ID: 37812437
[TBL] [Abstract][Full Text] [Related]
3. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
[TBL] [Abstract][Full Text] [Related]
5. Continuity of care (COC) and amyloid-β PET scan: the CARE-IDEAS study.
O'Brien EC; Ford CB; Sorenson C; Jutkowitz E; Shepherd-Banigan M; Van Houtven C
Alzheimers Res Ther; 2023 Jan; 15(1):6. PubMed ID: 36611213
[TBL] [Abstract][Full Text] [Related]
6. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
de Wilde A; van der Flier WM; Pelkmans W; Bouwman F; Verwer J; Groot C; van Buchem MM; Zwan M; Ossenkoppele R; Yaqub M; Kunneman M; Smets EMA; Barkhof F; Lammertsma AA; Stephens A; van Lier E; Biessels GJ; van Berckel BN; Scheltens P
JAMA Neurol; 2018 Sep; 75(9):1062-1070. PubMed ID: 29889941
[TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study.
Wilkins CH; Windon CC; Dilworth-Anderson P; Romanoff J; Gatsonis C; Hanna L; Apgar C; Gareen IF; Hill CV; Hillner BE; March A; Siegel BA; Whitmer RA; Carrillo MC; Rabinovici GD
JAMA Neurol; 2022 Oct; 79(11):1139-47. PubMed ID: 36190710
[TBL] [Abstract][Full Text] [Related]
8. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
Ossenkoppele R; Rabinovici GD; Smith R; Cho H; Schöll M; Strandberg O; Palmqvist S; Mattsson N; Janelidze S; Santillo A; Ohlsson T; Jögi J; Tsai R; La Joie R; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; Choi JY; Ryu YH; Lyoo CH; Hansson O
JAMA; 2018 Sep; 320(11):1151-1162. PubMed ID: 30326496
[TBL] [Abstract][Full Text] [Related]
9. Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management.
Shimohama S; Tezuka T; Takahata K; Bun S; Tabuchi H; Seki M; Momota Y; Suzuki N; Morimoto A; Iwabuchi Y; Kubota M; Yamamoto Y; Sano Y; Shikimoto R; Funaki K; Mimura Y; Nishimoto Y; Ueda R; Jinzaki M; Nakahara J; Mimura M; Ito D
Neurology; 2023 Jan; 100(3):e264-e274. PubMed ID: 36175151
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
[TBL] [Abstract][Full Text] [Related]
11. Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.
Iaccarino L; La Joie R; Lesman-Segev OH; Lee E; Hanna L; Allen IE; Hillner BE; Siegel BA; Whitmer RA; Carrillo MC; Gatsonis C; Rabinovici GD
JAMA Neurol; 2021 Feb; 78(2):197-207. PubMed ID: 33252608
[TBL] [Abstract][Full Text] [Related]
12. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.
Hu Y; Kirmess KM; Meyer MR; Rabinovici GD; Gatsonis C; Siegel BA; Whitmer RA; Apgar C; Hanna L; Kanekiyo M; Kaplow J; Koyama A; Verbel D; Holubasch MS; Knapik SS; Connor J; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE; West T
JAMA Netw Open; 2022 Apr; 5(4):e228392. PubMed ID: 35446396
[TBL] [Abstract][Full Text] [Related]
13. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected].
Ma Y; Zhang S; Li J; Zheng DM; Guo Y; Feng J; Ren WD
Medicine (Baltimore); 2014 Dec; 93(27):e150. PubMed ID: 25501055
[TBL] [Abstract][Full Text] [Related]
14. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
[TBL] [Abstract][Full Text] [Related]
16. A modified method of 3D-SSP analysis for amyloid PET imaging using [¹¹C]BF-227.
Kaneta T; Okamura N; Minoshima S; Furukawa K; Tashiro M; Furumoto S; Iwata R; Fukuda H; Takahashi S; Yanai K; Kudo Y; Arai H
Ann Nucl Med; 2011 Dec; 25(10):732-9. PubMed ID: 21792587
[TBL] [Abstract][Full Text] [Related]
17. Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
Kuhn E; Perrotin A; La Joie R; Touron E; Dautricourt S; Vanhoutte M; Vivien D; de La Sayette V; Chételat G;
Neurology; 2023 Jun; 100(24):e2454-e2465. PubMed ID: 37085328
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Amyloid Positron Emission Tomographic Positivity in Poststroke Mild Cognitive Impairment.
Wollenweber FA; Därr S; Müller C; Duering M; Buerger K; Zietemann V; Malik R; Brendel M; Ertl-Wagner B; Bartenstein P; Rominger A; Dichgans M
Stroke; 2016 Oct; 47(10):2645-8. PubMed ID: 27539301
[TBL] [Abstract][Full Text] [Related]
19. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
Strikwerda-Brown C; Hobbs DA; Gonneaud J; St-Onge F; Binette AP; Ozlen H; Provost K; Soucy JP; Buckley RF; Benzinger TLS; Morris JC; Villemagne VL; Doré V; Sperling RA; Johnson KA; Rowe CC; Gordon BA; Poirier J; Breitner JCS; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):975-985. PubMed ID: 35907254
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
